Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection unde…
Biotechnology
US, San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Vir Biotechnology, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | - | -1.835 | - | 9 | - | -246 | - | -3 | - | -3 | - | 102 |
| 2020 | -1.6200 | -2.386 | 0.71 | 79 | -174 | -169 | -177 | -164 | -326 | -254 | 37 | 48 |
| 2021 | -2.5100 | 2.704 | 67 | 905 | -298 | 341 | -296 | 374 | -598 | -286 | 70 | 423 |
| 2022 | 4.0700 | 4.313 | 1,087 | 1,712 | 528 | 396 | 282 | 428 | 420 | -304 | 160 | 431 |
| 2023 | 3.8900 | -4.660 | 1,580 | 79 | 515 | -615 | 944 | -34 | 833 | -285 | 161 | 895 |
| 2024 | -4.5900 | -3.841 | 86 | 68 | -615 | -515 | -641 | -29 | -661 | -29 | 174 | 771 |
| 2025 | - | -3.723 | - | 30 | - | -540 | - | -13 | - | -13 | - | 341 |
| 2026 | - | -3.734 | - | 48 | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
| 2027 | - | -2.928 | - | 195 | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
| 2028 | - | -3.000 | - | 475 | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Equal-Weight
Prev. Grade
Equal-Weight
Nov. 28, 2024
Equal-Weight
JP Morgan Chase
1Y Ago:
Equal-Weight
Prev. Grade
Overweight
Nov. 28, 2024
Equal-Weight
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-246.831% $22.98 · MISS
Nov. 6, 2024Price Then
$9.64
Price Target
$32.29
Price Now
$9.31